Navigation Links
Cylex Announces Valuable Personnel Additions

COLUMBIA, Md., March 16 /PRNewswire/ -- Cylex™, a global life science company that develops and manufactures in vitro diagnostic products based on patented technology, announced today the expansion of its growing staff with the hiring of Chari-Beth White, Marc Mendels and Julie Fudoli as well as the promotion of James E. "Jim" Brosius.

(Logo: )

"Due to the Company's rapid business development and growth in 2009, we are pleased to announce expansion of our presence throughout North America and abroad. In order to meet our infrastructure development goals, we are extremely pleased that these talented individuals are now with Cylex," said Jack Kromar, Vice President, Sales and Marketing.

Chari Beth White brings significant experience to Cylex as National Sales Manager – over 18 years of progressive sales/marketing and management experience with several major U.S. biotechnology research and pharmaceutical corporations including Gilead Sciences, Inc., Agouron Pharmaceuticals, Pharmacia & Upjohn, and Schering-Plough Pharmaceuticals. Chari Beth will assume responsibility for the direct management and leadership of field-based Business Development Managers. She will deliver sales and market share objectives, develop and execute the Cylex sales plan, and assist by providing solutions that meet customer needs.

Marc Mendels begins his role of Medical Science Liaison (MSL) and comes with extensive experience as a Senior MSL from Astellas and Wyeth Pharmaceuticals, over 16 years of experience in the transplant market, and sales experience from Schering-Plough and Johnson & Johnson. As an MSL, Marc will be a field-based member of the Medical Affairs support team responsible for the application of scientific knowledge and experience to organize the collection of and to analyze clinical data; educate physicians and transplant coordinators; and to establish and maintain clinical/scientific relationships with key opinion leaders, researchers, transplant coordinators, laboratory managers, and other members of the scientific community.

Julie Fudoli joins Cylex as a Business Development Manager, and has over 14 years of experience in sales and sales management. She successfully developed and managed the CVS/Caremark transplant team as the National Transplant Manager for CVS/Caremark and has also been involved with the transplant community as the National Board Treasurer of the Transplant Recipient International Organization (TRIO) and a member of the National Foundation for Transplant (NFT). Julie will continue to build strong business relationships with clinical decision makers and the consumers of our products.

"These individuals further strengthen the Sales and Medical Affairs teams at Cylex, and also complement the newly created position, Manager, International Sales and Marketing filled by recently promoted Jim Brosius," added Kromar.

James ("Jim") E. Brosius was promoted to International Manager, Sales and Marketing and will focus on and grow Cylex international business, since Cylex continues to see increasing interest and demand in international markets for ImmuKnow. Jim has a thorough understanding of the value of ImmuKnow in transplantation, a significant depth of knowledge within the transplant field, and a demonstrated ability to communicate and build relationships with key opinion leaders and clinicians. Jim's focus on our international opportunities will accelerate Cylex's ability to increase the global use and sales of ImmuKnow.

According to Kromar, "Today marks another very exciting moment at Cylex. The growth that we experienced both within our sales and staff expansion has catapulted us within the transplant market. Each of our new and promoted employees dramatically enhances our ability to foster continued innovation and business development in transplantation."

About Cylex, Inc.

Cylex is a privately held global life science company that is the leader in the development and manufacture of in vitro diagnostic products. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD USA. For more information, visit

About ImmuKnow

ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. For more information, visit

SOURCE Cylex, Inc.

Back to top



SOURCE Cylex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
2. Cylex Announces Brad L. Stewart as President of the Company
3. Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications
4. Cylex, Inc. Appoints Brad L. Stewart as Chief Executive Officer and Chairman of the Board
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
(Date:10/12/2015)... SAN FRANCISCO , October 12, 2015 ... reach USD 6.49 billion by 2022, according to a new ... can be attributed to rise in incidence of oncology diseases ... detection market is expected to reach USD 6.49 billion ... Research, Inc. This growth in demand can be attributed to ...
(Date:10/12/2015)... 12, 2015  Patara Pharma, a clinical-stage biotechnology ... diseases and conditions, today announced the closing of ... Concurrent with the close of its sale of ... and Security Agreement with Silicon Valley Bank whereby ... Patara will use the funds from the financing ...
(Date:10/12/2015)... Belgium , Oct. 12, 2015 VolitionRx ... from a completed clinical study of its NuQ ® ... in the online issue of Clinical Epigenetics , the ... was conducted in collaboration with Lund ... Roland Andersson , MD, PhD, Professor of Surgery and Vice-Dean, ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... LifeTrak ... the launch of LifeTrak Zoom, the world’s first amphibious fitness tracker that seeks to ... offers flexwear technology and accurate heart rate monitoring both in water and ...
Breaking Biology Technology:
(Date:10/12/2015)... Hoyos Labs , ... will introduce its new biometric four-finger (4F) ... providing an unprecedented level of security / ... new biometric standard for secure transactions (BOPS). ... financial services to healthcare are implementing Hoyos, ...
(Date:10/12/2015)... Oct. 12, 2015 Research and Markets ... the "Iris Recognition Market by Component (Hardware ... Control & Others), Industry (Travel & Immigration, Military ... Forecast to 2020" report to their offering. ... Iris Recognition Market worth 3627.90 Million USD ...
(Date:10/8/2015)... Oct. 8, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial ... on Thursday, October 22, 2015, after the close ... conference call for analysts and investors at 2:00 ... may discuss forward-looking information. ...
Breaking Biology News(10 mins):